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Immunofluorescent imaging has been a powerful
technique in helping to identify intracellular nuclear
and cytoplasmic molecules which are target antigens
of autoantibodies in systemic autoimmune disorders.
Patterns of staining can be correlated with molecules
engaged in specific cellular functions and distributed
in distinct cellular domains. Different autoimmune
disorders have different profiles of autoantibodies,
and immunodiagnostics has become an important
adjunct in differential diagnosis. An important finding
that has eluded explanation is the presence of
autoantibodies to many different antigens,
manifested strikingly in systemic lupus erythematosus.
In cancer, the occurrence of autoantibodies to
tumor-associated antigens is not uncommon and a
characteristic feature is also the presence of multiple
autoantibodies. The targeted tumor-associated
antigens are either oncogene or tumor suppressor
gene products or their coactivators, which are altered
or mutated and driving the autoimmune response.
Most cancer cells have between two and eight
mutated genes before oncogenic transformation
occurs, initiating a process called synthetic lethality in
tumorigenesis pathways. These observations beg the
question of whether there are similar mechanisms in
systemic lupus erythematosus and other disorders
driving autoimmunity pathways. Targeting molecules
that are synthetic lethal to each other is in the
forefront of the search for anticancer therapy, and this
could also be an objective in systemic autoimmune
disorders.Correspondence: emtan@scripps.edu
The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037,
USA
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Antinuclear antibodies (ANAs) have been used for several
decades as diagnostic biomarkers and are involved in
autoantibody-mediated immune complex inflammation in
the kidney, lung, brain, skin, joints and many other organs
[1,2]. Many of the major nuclear and cytoplasmic compo-
nents which are the target antigens of these autoantibodies
have been identified, but the reasons why these cellular
components acquired immunogenicity and induced auto-
antibody formation are largely unknown. Elucidation of this
enigma is arising from studies of autoantibodies to tumor-
associated antigens (TAAs) in cancer, suggesting that, in
addition to their known roles in diagnosis and pathogenesis,
ANAs might be revealing the cellular components involved
in autoimmunity pathways in the way that autoantibodies to
TAAs inform on partners in tumorigenesis pathways.Some unique features of antinuclear antibodies in
systemic autoimmune disorders
The immunofluorescent imaging technique, using tissue
culture cells such as HEp2 (an epithelial tumor cell line) as
the substrate for reaction with autoimmune sera, has been
an important technique for detecting ANAs. Figure 1 shows
autoantibodies in systemic lupus erythematosus (SLE) bind-
ing to particles in the nucleoplasm of HEp2 cells, but no
binding to any component in the cytoplasm. Subsequent
studies have shown that this is a staining pattern characteris-
tic of autoantibodies reacting with Sm antigen, a complex of
small nuclear RNA and proteins called snRNPs, which are
involved in the processing of precursor mRNAs to mature
mRNAs [2]. Autoantibodies to Sm are unique to SLE.
Figure 2 shows the reaction of another SLE autoantibody
reacting with proliferating cell nuclear antigen in nuclei of
cells that are in the S (DNA synthesis) phase of the cell
cycle. The different sizes and densities of speckled staining
relate to early or late stages of DNA synthesis [3]. There was
at first some skepticism concerning the importance and
significance of ANA staining patterns, but this was in large
part due to lack of appreciation of the structure, function
and location of intracellular micro-organelles.
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Figure 1 Immunofluorescence histochemistry depicting the Sm
staining pattern on HEp2 cells using autoantibodies to Sm in the
sera of patients with systemic lupus erythematosus. Sm antigen has
been identified as a component of mRNA splicing particles distributed in
the nucleoplasm in the size and location shown here. This pattern has
been called nuclear speckles. The cytoplasm is nonreactive with the
antibody and the nucleolar domains contain a few small speckles.
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immune disorders and it became clear that some ANAs
were highly specific and associated predominantly with one
disease, such as autoantibodies to double-strand DNA and
to Sm antigen in SLE, anti-DNA topoisomerase 1 and anti-Figure 2 Immunofluorescence histochemistry depicting the
proliferating cell nuclear antigen staining pattern. The antibody
in this systemic lupus erythematosus serum reacts with proliferating
cell nuclear antigen (PCNA), identified as an auxiliary protein of DNA
polymerase delta that is involved in DNA synthesis. PCNA is seen to
localize in nuclei that are in the S phase of the cell cycle, and the
variation in size and density of speckled staining is related to early
or late stages of the S phase. The nuclei of cells in interphase which
are not in DNA synthesis do not react with the antibody. The
cytoplasm was counterstained (orange) to delineate cytoplasm from
the yellow–green speckled staining of PCNA particles in the nucleus.
Note: This article is part of the collection Research through
the eyes of pioneers. Other articles in this series can be found at
http://arthritis-research.com/series/pioneers.
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anti-transfer RNA synthetases in dermato/polymyositis.
Other ANAs such as anti-histones are present in several dis-
eases, including SLE and rheumatoid arthritis. Nevertheless,
combinations of ANAs with high specificity and others with
lower specificity produced different ANA profiles that were
useful in differential diagnosis of clinical disorders. Testing
for ANAs is now a widely used tool in the diagnostic arma-
mentarium of the rheumatologist.
In almost every patient with systemic autoimmune
disease, there is multiplicity of autoantibodies present at
the same time. In SLE, antibody to double-stranded DNA,
anti-Sm and anti-histones might occur concurrently. In
scleroderma, antibody to DNA topoisomerase 1 and anti-
nucleolar antibodies are often present together. In many
instances, autoantibodies of three or more specificities
might be present. This phenomenon is an enigma that has
not been elucidated.
Tumorigenesis pathways and autoimmunity
pathways
One-third of patients with chronic hepatitis and liver
cirrhosis eventually develop hepatocellular carcinoma. We
examined serial serum samples and showed that autoanti-
bodies were detectable in the pre-cancer period, but novel
autoantibodies appeared with transformation to hepatocel-
lular carcinoma. The molecular targets of these novel auto-
antibodies were identified as insulin-like growth factors
[4,5], coregulators of oncogenes [6,7], or tumor suppressor
genes [8,9]. Extension of such studies to other types of solid
tumors showed frequent occurrence of autoantibodies to a
number of cellular antigens that have been called TAAs.
Other features include autoantibodies to multiple TAAs,
with the majority of patients having two or more anti-
bodies, a characteristic that recapitulates observations in
systemic autoimmune diseases.
Recent studies on genetic abnormalities in cancer have
helped in elucidating the immunological findings in cancer
that might contribute to clarifying similar questions in
systemic autoimmunity. In breast and colorectal cancers, a
typical tumor contains two to eight driver-gene mutations
that modulate or alter signaling pathways [10,11]. These
driver genes include c-myc (an oncogene) and p53 (a tumor
suppressor gene), and both gene products are TAAs and
major targets of anti-TAA autoantibodies. To date, as many
as 140 genes have been identified as driver genes, and
mutations in several genes combine to confer growth
advantage to cancer cells.
The concept of synthetic lethality in cancer is based on
early observations in yeast and Drosophila that have been
extended to higher organisms [12,13]. When two genes are
synthetic lethal, mutation in one gene alone is nonlethal
but simultaneous mutation in both genes is lethal. This
concept has been expanded to include the situation calledsynthetic sickness/lethality. One example of the synthetic
sickness/lethality concept is where dysfunction of the breast
tumor suppressor gene BRCA1/2 is synthetically lethal with
inhibition of the DNA repair enzyme poly(ADP-ribose)
polymerase 1, and this combination of events leads to onco-
genesis [13]. The implications of this concept explain why
multiple genetic mutations are found in tumors because one
mutation alone may not be lethal, and some multiple
mutations may be synthetically lethal but others may not be
synthetically lethal until the right combination occurs. Auto-
immune response to the altered gene products would result
in the production of autoantibodies.
Genetic studies in cancer have been highly productive
partly because the target cell for analysis can be readily
accessed. In systemic autoimmunity, such as SLE, the
target cell that drives autoimmune responses is unknown.
However, by making antibodies, the immune system is
also reporting the identity of players in the pathway to
autoimmunity [14]. There are many murine models of
autoimmunity that would be useful in exploring potential
autoimmunity pathways. In addition to advancing our
knowledge of basic mechanisms in autoimmunity, there is
the likelihood of developing an approach to therapy by
targeting molecules that are synthetic sickness/lethal to
each other. The latter approach is at the forefront of the
search for anticancer therapy [15,16].Abbreviations
ANA: Antinuclear antibody; SLE: Systemic lupus erythematosus;
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